312 related articles for article (PubMed ID: 22155366)
1. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.
Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Masyuk AI; Gradilone SA; Gajdos GB; Chandok N; Bakeberg JL; Ward CJ; Ritman EL; Kiyokawa H; LaRusso NF
Gastroenterology; 2012 Mar; 142(3):622-633.e4. PubMed ID: 22155366
[TBL] [Abstract][Full Text] [Related]
2. VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice.
Amura CR; Brodsky KS; Groff R; Gattone VH; Voelkel NF; Doctor RB
Am J Physiol Cell Physiol; 2007 Jul; 293(1):C419-28. PubMed ID: 17475663
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease.
Lee SO; Masyuk T; Splinter P; Banales JM; Masyuk A; Stroope A; Larusso N
J Clin Invest; 2008 Nov; 118(11):3714-24. PubMed ID: 18949056
[TBL] [Abstract][Full Text] [Related]
4. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.
Masyuk TV; Masyuk AI; Torres VE; Harris PC; Larusso NF
Gastroenterology; 2007 Mar; 132(3):1104-16. PubMed ID: 17383431
[TBL] [Abstract][Full Text] [Related]
5. Distinct patterns of kidney and liver cyst growth in pkd2(WS25/-) mice.
Doctor RB; Serkova NJ; Hasebroock KM; Zafar I; Edelstein CL
Nephrol Dial Transplant; 2010 Nov; 25(11):3496-504. PubMed ID: 20388629
[TBL] [Abstract][Full Text] [Related]
6. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.
Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Gradilone SA; Huang B; Masyuk AI; Hogan MC; Torres VE; Larusso NF
Hepatology; 2013 Jul; 58(1):409-21. PubMed ID: 23172758
[TBL] [Abstract][Full Text] [Related]
7. Telmisartan ameliorates fibrocystic liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.
Yoshihara D; Kugita M; Sasaki M; Horie S; Nakanishi K; Abe T; Aukema HM; Yamaguchi T; Nagao S
PLoS One; 2013; 8(12):e81480. PubMed ID: 24324698
[TBL] [Abstract][Full Text] [Related]
8. Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression.
Masyuk TV; Lee SO; Radtke BN; Stroope AJ; Huang B; Banales JM; Masyuk AI; Splinter PL; Gradilone SA; Gajdos GB; LaRusso NF
Am J Pathol; 2014 Jan; 184(1):110-21. PubMed ID: 24211536
[TBL] [Abstract][Full Text] [Related]
9. TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling.
Masyuk TV; Masyuk AI; Lorenzo Pisarello M; Howard BN; Huang BQ; Lee PY; Fung X; Sergienko E; Ardecky RJ; Chung TDY; Pinkerton AB; LaRusso NF
Hepatology; 2017 Oct; 66(4):1197-1218. PubMed ID: 28543567
[TBL] [Abstract][Full Text] [Related]
10. The zebrafish as a model to study polycystic liver disease.
Tietz Bogert PS; Huang BQ; Gradilone SA; Masyuk TV; Moulder GL; Ekker SC; Larusso NF
Zebrafish; 2013 Jun; 10(2):211-7. PubMed ID: 23668934
[TBL] [Abstract][Full Text] [Related]
11. Autophagy-mediated reduction of miR-345 contributes to hepatic cystogenesis in polycystic liver disease.
Masyuk T; Masyuk A; Trussoni C; Howard B; Ding J; Huang B; LaRusso N
JHEP Rep; 2021 Oct; 3(5):100345. PubMed ID: 34568801
[TBL] [Abstract][Full Text] [Related]
12. Insignificant effect of secretin in rodent models of polycystic kidney and liver disease.
Wang X; Ye H; Ward CJ; Chu JY; Masyuk TV; Larusso NF; Harris PC; Chow BK; Torres VE
Am J Physiol Renal Physiol; 2012 Oct; 303(7):F1089-98. PubMed ID: 22811488
[TBL] [Abstract][Full Text] [Related]
13. Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease.
Wang X; Harris PC; Somlo S; Batlle D; Torres VE
Nephrol Dial Transplant; 2009 Feb; 24(2):526-34. PubMed ID: 18826972
[TBL] [Abstract][Full Text] [Related]
14. Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease.
Spirli C; Mariotti V; Villani A; Fabris L; Fiorotto R; Strazzabosco M
J Hepatol; 2017 Mar; 66(3):571-580. PubMed ID: 27826057
[TBL] [Abstract][Full Text] [Related]
15. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.
Munoz-Garrido P; Marin JJ; Perugorria MJ; Urribarri AD; Erice O; Sáez E; Úriz M; Sarvide S; Portu A; Concepcion AR; Romero MR; Monte MJ; Santos-Laso Á; Hijona E; Jimenez-Agüero R; Marzioni M; Beuers U; Masyuk TV; LaRusso NF; Prieto J; Bujanda L; Drenth JP; Banales JM
J Hepatol; 2015 Oct; 63(4):952-61. PubMed ID: 26044126
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of NAE-dependent protein hyper-NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease.
Lee-Law PY; Olaizola P; Caballero-Camino FJ; Izquierdo-Sanchez L; Rodrigues PM; Perugorria MJ; Azkargorta M; Elortza F; Martinez-Chantar ML; Aspichueta P; Marzioni M; Bujanda L; Drenth JPH; Banales JM
United European Gastroenterol J; 2021 Sep; 9(7):848-859. PubMed ID: 34310849
[TBL] [Abstract][Full Text] [Related]
17. Nonselective Cyclooxygenase Inhibition Retards Cyst Progression in a Murine Model of Autosomal Dominant Polycystic Kidney Disease.
Zhang M; Srichai MB; Zhao M; Chen J; Davis LS; Wu G; Breyer MD; Hao CM
Int J Med Sci; 2019; 16(1):180-188. PubMed ID: 30662341
[No Abstract] [Full Text] [Related]
18. Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target.
Masyuk AI; Masyuk TV; Lorenzo Pisarello MJ; Ding JF; Loarca L; Huang BQ; LaRusso NF
Hepatology; 2018 Mar; 67(3):1088-1108. PubMed ID: 29023824
[TBL] [Abstract][Full Text] [Related]
19. Hepato-renal pathology in pkd2ws25/- mice, an animal model of autosomal dominant polycystic kidney disease.
Stroope A; Radtke B; Huang B; Masyuk T; Torres V; Ritman E; LaRusso N
Am J Pathol; 2010 Mar; 176(3):1282-91. PubMed ID: 20093497
[TBL] [Abstract][Full Text] [Related]
20. A role for microRNA in cystic liver and kidney diseases.
Chu AS; Friedman JR
J Clin Invest; 2008 Nov; 118(11):3585-7. PubMed ID: 18949060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
